

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSIL may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSIL has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Hepatitis C

Policy Number: CPCPLAB015

Version 1.0

Enterprise Medical Policy Committee Approval Date: January 25, 2022

Plan Effective Date: May 1, 2022

Description

BCBSIL has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

1. Screening at least once in a lifetime for Hepatitis C infection **may be reimbursable** for adults between the ages of 18 years and 79 years.
2. Testing for Hepatitis C infection for all adults (≥ 18 years old) with recognized conditions or exposures **may be reimbursable** in the following situations:
 - a. Illicit intranasal or injectable drug use:
 - b. Receipt of clotting factor concentrates produced before 1987

- c. History of hemodialysis
 - d. Evidence of liver disease (based on clinical presentation, persistently abnormal alanine aminotransferase (ALT) levels, or abnormal liver function studies)
 - e. Presence of HIV infection
 - f. Receipt of an organ transplant before July 1992
 - g. Receipt of a blood transfusion or blood component before July 1992.
 - h. Individuals notified that they received blood from a donor who later tested positive for an HCV infection
 - i. History of incarceration
 - j. Receipt of a tattoo in an unregulated setting
 - k. Healthcare, emergency medical, and public safety workers after needle sticks, sharps, or mucosal exposures to HCV-positive blood
 - l. Children born to HCV-positive women
 - m. Current sexual partners of HCV-infected persons
3. Routine periodic HCV testing **may be reimbursable** for individuals with ongoing risk factors, while risk factors persist:
 - a. Individuals who currently inject drugs and share needles, syringes, or other drug preparation equipment
 - b. Individuals who are receiving ongoing hemodialysis
 4. One-time testing for HCV genotype **may be reimbursable** prior to initiation of treatment to guide selection of the most appropriate antiviral regimen.
 5. For patients with acute HCV infection, monitoring HCV RNA **may be reimbursable** to determine spontaneous clearance of HCV infection versus persistence of infection. Testing can be performed every 4 to 8 weeks for 6 to 12 months.
 6. Testing for HCV viral load, using a quantitative nucleic acid test, **may be reimbursable** in the following situations:
 - a. prior to initiation of HCV therapy, AND
 - b. after 4 weeks of therapy AND
 - c. at the end of treatment AND
 - d. 12 weeks and 24 weeks after completion of treatment.

Procedure Codes

Codes
86803, 86804, 87520, 87521, 87522, 87902, G0472

References:

AASLD-IDSA. (2015). Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. *Hepatology*, 62(3), 932-954. doi:10.1002/hep.27950

AASLD-IDSA. (2017). Management of Acute HCV Infection. Retrieved from

<https://www.hcvguidelines.org/unique-populations/acute-infection>

AASLD-IDSA. (2018a). HCV Testing and Linkage to Care. Retrieved from <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

AASLD-IDSA. (2018b). Monitoring Patients Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Therapy. Retrieved from <https://www.hcvguidelines.org/evaluate/monitoring>

AASLD-IDSA. (2019). HCV Testing and Linkage to Care. Retrieved from <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

AASLD-IDSA. (2020). HCV Testing and Linkage to Care. Retrieved from <https://www.hcvguidelines.org/evaluate/testing-and-linkage>

AASLD. (2014). Retrieved from <http://www.choosingwisely.org/clinician-lists/american-association-study-liver-disease-hepatitis-c-viral-load-testing/>

Abbott. (2020). SD BIOLINE HCV. Retrieved from <https://www.alere.com/en/home/product-details/sd-bioline-hcv.html>

Ansaldi, F., Orsi, A., Sticchi, L., Bruzzone, B., & Icardi, G. (2014). Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. *World J Gastroenterol*, 20(29), 9633-9652. doi:10.3748/wjg.v20.i29.9633

Bailey, J. R., Barnes, E., & Cox, A. L. (2019). Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. *Gastroenterology*, 156(2), 418-430. doi:10.1053/j.gastro.2018.08.060

BioMérieux. (2018). VIDAS® Hepatitis panel. Retrieved from <https://www.biomerieux.com.au/product/vidas-hepatitis-panel>

Boucher, M., & Gruslin, A. (2017). No. 96-The Reproductive Care of Women Living With Hepatitis C Infection. *J Obstet Gynaecol Can*, 39(7), e1-e25. doi:10.1016/j.jogc.2017.04.007

CDC. (2012). Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm>

CDC. (2015a). Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxycodone — Indiana, 2015. Retrieved from <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6416a4.htm>

CDC. (2015b). Testing Recommendations for Hepatitis C Virus Infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>

CDC. (2016a). Hepatitis C. Retrieved from <https://www.cdc.gov/dotw/hepatitisc/index.html>

CDC. (2016b). Surveillance for Viral Hepatitis – United States, 2016. Retrieved from <https://www.cdc.gov/hepatitis/statistics/2016surveillance/commentary.htm>

CDC. (2018). Surveillance for Viral Hepatitis – United States, 2018. Retrieved from

<https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepC.htm>

CDC. (2020a). Hepatitis C. Retrieved from <https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm>

CDC. (2020b). Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus — CDC Guidance, United States, 2020. Retrieved from https://www.cdc.gov/mmwr/volumes/69/rr/rr6906a1.htm?s_cid=rr6906a1_w#suggestedcitation

CDC. (2020c). Testing Recommendations for Hepatitis C Virus Infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>

Chen, Y., Ji, H., Shao, J., Jia, Y., Bao, Q., Zhu, J., . . . Shen, Y. (2019). Different Hepatitis C Virus Infection Statuses Show a Significant Risk of Developing Type 2 Diabetes Mellitus: A Network Meta-Analysis. *Dig Dis Sci*. doi:10.1007/s10620-019-05918-7

Chevaliez, S., Wlassow, M., Volant, J., Roudot-Thoraval, F., Bachelard, A., Poiteau, L., . . . Dominguez, S. (2020). Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. *Open Forum Infect Dis*, 7(6), ofaa196. doi:10.1093/ofid/ofaa196

Chopra, S. (2018). Clinical manifestations and natural history of chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C&topicRef=3673&source=see_link#H349503874

Chopra, S. (2019). Clinical manifestations and natural history of chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/clinical-manifestations-and-natural-history-of-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C&topicRef=3673&source=see_link#H349503874

Chopra, S., Arora, Sanjeev. (2018). Screening for chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/screening-for-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C%20screening&source=search_result&selectedTitle=1~79&usage_type=default&display_rank=1

Chopra, S., Arora, Sanjeev. (2020). Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/patient-evaluation-and-selection-for-antiviral-therapy-for-chronic-hepatitis-c-virus-infection?sectionName=HCV%20genotype&search=Hepatitis%20C&topicRef=89950&anchor=H620697012&source=see_link#H620697012

Chopra, S., Muir, Andrew. (2020). Treatment regimens for chronic hepatitis C virus genotype 1 infection in adults. Retrieved from https://www.uptodate.com/contents/treatment-regimens-for-chronic-hepatitis-c-virus-genotype-1-infection-in-adults?search=Hepatitis%20C&topicRef=3668&source=see_link

Chopra, S., Pockros, Paul. (2020). Overview of the management of chronic hepatitis C virus infection. Retrieved from https://www.uptodate.com/contents/overview-of-the-management-of-chronic-hepatitis-c-virus-infection?search=Hepatitis%20C&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H9643992

CTFPHC. (2017). Recommendations on hepatitis C screening for adults. Retrieved from

<https://www.cmaj.ca/content/cmaj/189/16/E594.full.pdf>

EASL. (2018). EASL Recommendations on Treatment of Hepatitis C 2018. *J Hepatol*, 69(2), 461-511. doi:10.1016/j.jhep.2018.03.026

EASL. (2020). EASL recommendations on treatment of Hepatitis C 2020. Retrieved from <https://easl.eu/wp-content/uploads/2020/10/EASL-recommendations-on-treatment-of-hepatitis-C.pdf>

Hagan, H., Campbell, J., Thiede, H., Strathdee, S., Ouellet, L., Kapadia, F., . . . Garfein, R. S. (2006). Self-reported hepatitis C virus antibody status and risk behavior in young injectors. *Public Health Rep*, 121(6), 710-719. doi:10.1177/003335490612100611

IHS. (2021). Hepatitis C and Tuberculosis Screening. Retrieved from <https://www.ihs.gov/diabetes/clinician-resources/soc/hepc-tb-screening/>

Inoue, J., Kanno, A., Wakui, Y., Miura, M., Kobayashi, T., Morosawa, T., . . . Shimosegawa, T. (2017). Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment. *Tohoku J Exp Med*, 241(1), 21-28. doi:10.1620/tjem.241.21

Jacobson, I. M., Lim, J. K., & Fried, M. W. (2017). American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection. *Gastroenterology*, 152(6), 1578-1587. doi:10.1053/j.gastro.2017.03.018

JMitra&Co. (2015). HCV TRI-DOT. Retrieved from http://www.jmitra.co.in/ourdivision/diagnosticdivision/rapidtestkits/hcvrange/hcv_tri_dot.aspx

Kanwal, F., Bacon, B. R., Beste, L. A., Brill, J. V., Gifford, A. L., Gordon, S. C., . . . Younossi, Z. M. (2017). Hepatitis C Virus Infection Care Pathway; A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group. *Gastroenterology*, 152(6), 1588-1598. doi:10.1053/j.gastro.2017.03.039

Legacy_Health. (2021). Hepatitis Chronic Panel. Retrieved from <https://www.legacyhealth.org/for-health-professionals/refer-a-patient/laboratory-services/test-table/hepatitis-chronic-panel>

Lexicomp. (2019). Ledipasvir and sofosbuvir: Drug information. Retrieved from https://www.uptodate.com/contents/ledipasvir-and-sofosbuvir-drug-information?search=Hepatitis%20C&topicRef=16592&source=see_link

Linthicum, M. T., Gonzalez, Y. S., Mulligan, K., Moreno, G. A., Dreyfus, D., Juday, T., . . . Brookmeyer, R. (2016). Value of expanding HCV screening and treatment policies in the United States. *Am J Manag Care*, 22(6 Spec No.), Sp227-235. Retrieved from <https://www.ajmc.com/journals/issue/2016/2016-5-vol22-sp/value-of-expanding-hcv-screening-and-treatment-policies-in-the-united-states?p=1>

Messina, J. P., Humphreys, I., Flaxman, A., Brown, A., Cooke, G. S., Pybus, O. G., & Barnes, E. (2015). Global distribution and prevalence of hepatitis C virus genotypes. *Hepatology*, 61(1), 77-87. doi:10.1002/hep.27259

Moreno, G. A., Mulligan, K., Huber, C., Linthicum, M. T., Dreyfus, D., Juday, T., . . . Lakdawalla, D. N. (2016). Costs and spillover effects of private insurers' coverage of hepatitis C treatment. *Am J Manag Care*, 22(6 Spec No.),

Sp236-244. Retrieved from <https://www.ajmc.com/journals/issue/2016/2016-5-vol22-sp/costs-and-spillover-effects-of-private-insurers-coverage-of-hepatitis-c-treatment?p=1>

Moyer, V. A. (2013). Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*, 159(5), 349-357. doi:10.7326/0003-4819-159-5-201309030-00672

OraSure. (2013). OraQuick® HCV test Retrieved from <https://www.orasure.com/products-infectious/products-infectious-oraquick-hcv.asp>

Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., . . . Wong, J. B. (2020). Screening for Hepatitis C Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. *Jama*. doi:10.1001/jama.2020.1123

Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., . . . Estes, C. (2014). The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. *J Viral Hepat*, 21 Suppl 1, 34-59. doi:10.1111/jvh.12248

Rein, D. B., Smith, B. D., Wittenborn, J. S., Lesesne, S. B., Wagner, L. D., Roblin, D. W., . . . Weinbaum, C. M. (2012). The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. *Ann Intern Med*, 156(4), 263-270. doi:10.7326/0003-4819-156-4-201202210-00378

Saeed, Y. A., Phoon, A., Bielecki, J. M., Mitsakakis, N., Bremner, K. E., Abrahamyan, L., . . . Wong, W. W. L. (2020). A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. *Value Health*, 23(1), 127-137. doi:10.1016/j.jval.2019.07.005

Shah, H., Bilodeau, M., Burak, K. W., Cooper, C., Klein, M., Ramji, A., . . . Feld, J. J. (2018). The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. *Canadian Medical Association Journal*, 190(22), E677. doi:10.1503/cmaj.170453

Simmonds, P. (2001). Reconstructing the origins of human hepatitis viruses. *Philos Trans R Soc Lond B Biol Sci*, 356(1411), 1013-1026. doi:10.1098/rstb.2001.0890

Spach. (2020). Hepatitis C Diagnostic Testing. Retrieved from <https://www.hepatitisc.uw.edu/go/screening-diagnosis/diagnostic-testing/core-concept/all>

USPSTF. (2013). Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med*, 159(5), 349-357. doi:10.7326/0003-4819-159-5-201309030-00672

Vetter, B. N., Reipold, E. I., Ongarello, S., Audu, R., Ige, F. A., Alkhazashvili, M., . . . Fransen, K. (2020). Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study. *The Journal of Infectious Diseases*. doi:10.1093/infdis/jiaa389

Wandeler, G., Schlauri, M., Jaquier, M. E., Rohrbach, J., Metzner, K. J., Fehr, J., . . . Yerly, S. (2015). Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. *Open Forum Infect Dis*, 2(1), ofv026. doi:10.1093/ofid/ofv026

WHO. (2016). WHO Guidelines Approved by the Guidelines Review Committee. In Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. Geneva: World Health Organization Copyright (c) World Health Organization 2016.

WHO. (2017). Guidelines on Hepatitis B and C Testing.

WHO. (2018). Guidelines for The Care And Treatment Of Persons Diagnosed With Chronic Hepatitis C Virus Infection. Retrieved from <https://apps.who.int/iris/bitstream/handle/10665/273174/9789241550345-eng.pdf?ua=1>

Policy Update History:

5/1/2022	New policy
----------	------------